Neuro-Oncology Reviews

Volume 28 Number 21
31 July 2026

Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 21, 31 July

Jia M, Cui G, Liu Z, Luo C.
Bibliometric analysis of programmed cell death and immunotherapy research in glioma.
Discov Oncol. 2026 Jul 21. doi: 10.1007/s12672-026-05535-7. PMID: 42481885. ˍ

Wang C, Sun Z, Sun J, Liu J, Zhao Q, Sun Y, Sun C.
Tumor microenvironment-responsive nanocarriers for enhanced glioblastoma immunotherapy.
J Nanobiotechnology. 2026 Jul 21. doi: 10.1186/s12951-026-04823-2. PMID: 42482062. ˍ

Chang SM, Huang MAC, Barbour M.
Pediatric Brain Tumors.
Adv Pediatr. 2026 May 22;73(1):269-282. doi: 10.1016/j.yapd.2025.11.002. PMID: 42481096˰ ˍ

Etter MM, Akeret K, Guzman R, Mariani L, Hutter G, Lim M.
Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice.
CNS Drugs. 2026 Jul 22. doi: 10.1007/s40263-026-01322-8. PMID: 42486970. ˍ

Wen W, Zhang Z, Wang Y, Zhu G, Zhang Q.
Reprogramming the vascular-immune niche: Towards a new therapeutic paradigm for glioblastoma.
Crit Rev Oncol Hematol. 2026 Jul 23;226:105500. doi: 10.1016/j.critrevonc.2026.105500. PMID: 42492866˰ ˍ

Sarma RK, Nath P, Bora P, Chetia P, Bala A.
Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies.
Int Immunopharmacol. 2026 Jul 24;187:117134. doi: 10.1016/j.intimp.2026.117134. PMID: 42497658˰ ˍ

Darko K, Tenkorang P, Osei-Tutu GJ, Asiedu O, Tahiru M, Nkrumah-Boateng P, Chen J, Fonkem E, Etame AB.
Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials.
Clin Transl Oncol. 2026 Jul 25. doi: 10.1007/s12094-026-04514-2. PMID: 42501205˰ ˍ

Filiberti S, Tavani C, Somenza E, Tassone N, d'Amati A, Turati M, Ronca R.
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors.
Med Res Rev. 2026 Jul 25. doi: 10.1002/med.70090. PMID: 42499273. ˍ

Ramirez-Ferrer E, Noll K, Mayorga-Corvacho J, Sierra MA, Furey C, Bugarini A, Zuluaga-Garcia JP, Asman P, Ene C, Ferguson SD, Weinberg JS, Lang FF, Duffau H, Prabhu SS.
Beyond motor: clinical manifestations of right hemisphere gliomas - a systematic review.
J Neurooncol. 2026 Jul 27;179(1):15. doi: 10.1007/s11060-026-05728-8. PMID: 42507250. ˍ

Guarnaccia M, Cavallaro S.
The Price of Precision: A Critical Review of Molecular Diagnostics in Glioma, From Guidelines to Global Disparities.
Ann Clin Transl Neurol. 2026 Jul 28:10.1002/acn3.70503. doi: 10.1002/acn3.70503. PMID: 42516044. ˍ

Monje M.
The neuroscience of childhood brain cancers.
Sci Transl Med. 2026 Jul 29;18(860):eaeg9138. doi: 10.1126/scitranslmed.aeg9138. PMID: 42525784˰ ˍ

Pasvolsky L, Jones GH, Vu Y, Winkler F, Amit M.
Cancer neuroscience: Mechanisms to medicine.
Sci Transl Med. 2026 Jul 29;18(860):eaeh1718. doi: 10.1126/scitranslmed.aeh1718. PMID: 42525788. ˍ

Villa GR, Patel AD, Reardon DA, Chiocca EA.
Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.
Sci Transl Med. 2026 Jul 29;18(860):eaeg8772. doi: 10.1126/scitranslmed.aeg8772. PMID: 42525786. ˍ

Parveen S, Konde DV, Paikray SK, Tripathy NS, Sahoo L, Samal HB, Dilnawaz F.
Nanoimmunotherapy: the smart trooper for cancer therapy.
Explor Target Antitumor Ther. 2025 Apr 10;6:1002308. doi: 10.37349/etat.2025.1002308. PMID: 40230883. ˍ

van de Langerijt KA, Kibria MG, Villa GR, Mineo M.
The Hallmarks of Glioblastoma: Functional Interplay Between Long Non-Coding RNAs and RNA-Binding Proteins.
Cells. 2026 Jul 11;15(14):1251. doi: 10.3390/cells15141251. PMID: 42505361. ˍ

Crombet Ramos T, Díaz Miqueli A, Pérez Rodríguez R.
Beyond Acute EGFR Blockade: Biological Basis and Clinical Evidence for Long-Term Nimotuzumab Therapy.
Biomedicines. 2026 Jul 14;14(7):1570. doi: 10.3390/biomedicines14071570. PMID: 42512043. ˍ

Omene E.
Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming.
Front Oncol. 2026 Jul 14;16:1849888. doi: 10.3389/fonc.2026.1849888. PMID: 42523684. ˍ

Saxena A, Bayik D.
Metabolism of myeloid cells in brain tumors.
Front Immunol. 2026 Jul 14;17:1894833. doi: 10.3389/fimmu.2026.1894833. PMID: 42523669. ˍ

Srinivasan S, Eraghi MM, Odiase P, Mazumder S, Ahuja A, Ranganathan S, Patel P, O'Leary S, Guirguis M, Barrie U, Sun MZ, Patel A.
Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.
J Clin Neurosci. 2026 Jul 20;152:112202. doi: 10.1016/j.jocn.2026.112202. PMID: 42475978. ˍ